# First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

> **NCT07284186** · PHASE1 · RECRUITING · sponsor: **Plexium, Inc.** · enrollment: 155 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma
- Gastric Adenocarcinoma
- Gastric Squamous Cell Carcinoma
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Metastatic Solid Tumor
- Non-Small Cell Lung Carcinoma
- Esophageal Adenocarcinoma
- SMARCA4 Mutation
- Gastroesophageal Junction Squamous Cell Carcinoma
- Advanced Solid Tumor

## Interventions

- **DRUG:** PLX-61639

## Key facts

- **NCT ID:** NCT07284186
- **Lead sponsor:** Plexium, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2029-12
- **Final completion:** 2030-09
- **Target enrollment:** 155 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07284186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07284186, "First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07284186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*